ERBB2 and breast cancer: Interestingly, the anti-VEGF-A drug bevacizumab failed to improve patients’ overall survival as a monotherapy at first, thus it was combined with paclitaxel for the HER2- metastatic BC and got Food and Drug Administration (FDA) approval, before withdrawal of this combination again due to efficacy issues and acquired resistance.